Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564194 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
A Phase 1 study of Infectious Disease and Respiratory Syncytial Virus (RSV), sponsored by Immorna Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 3
- Study locations
NCT06564194: Active Phase 1 study of Infectious Disease and Respiratory Syncytial Virus (RSV), sponsored by Immorna Biotherapeutics.
NCT06564194 is a Phase 1 study of Infectious Disease and Respiratory Syncytial Virus (RSV) that is active but no longer recruiting, run by Immorna Biotherapeutics. The registered enrollment target is 75 participants, below the 7,021-participant average among 18 other Infectious Disease trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06564194, a Phase 1 study of Infectious Disease and Respiratory Syncytial Virus (RSV), is active but no longer recruiting, sponsored by Immorna Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.
Primary Outcome
Frequency of SAEs characterized by type, severity, duration, and relationship to the JCXH-108 recorded from Day 1 (D1) post-vaccine administration through follow-up completion.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL JCXH-108
Study Locations (3)
Florida
- Health Awareness - Jupiter
Louisiana
- DelRicht - New Orleans - New Orleans
Missouri
- Sundance Clinical Research - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2025-06 |
| Phase | Phase 1 |
What the registry record for NCT06564194 still lists
NCT06564194 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 7,021-participant average among 18 other Infectious Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Infectious Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06564194 reports a single indexed study location in Florida, Louisiana, Missouri.
Frequently Asked Questions
What is clinical trial NCT06564194 about?
NCT06564194 is a clinical study titled "A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV". The goal of this clinical trial is to assess the safety, reactogenicity and immunogenicity of an mRNA-based vaccine, JCXH-108, the prevention of Respiratory Syncytial Virus (RSV) infection and diseases. Participants will be randomized to receive either JCXH-108 or placebo.
What is the current status of trial NCT06564194?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2024-09-25. Estimated completion is 2025-06.
What conditions does trial NCT06564194 study?
This clinical trial studies the following conditions: Infectious Disease, Respiratory Syncytial Virus (RSV).
What interventions are being tested in trial NCT06564194?
The interventions under investigation include: Placebo (OTHER), JCXH-108 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06564194?
This trial is sponsored by Immorna Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564194 being conducted?
This trial has 3 study locations across Florida, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infectious Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06564194's enrollment target sits among peer trials
75 14th of 18 higher than 4 of 18 other Infectious Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Infectious Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
COMPLETED · Phase 1
-
Compliant Analysis of Patient Samples and Data
RECRUITING
-
Collection and Distribution of Biospecimens for Novel Research Uses
RECRUITING
-
Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing
RECRUITING · NA
-
Triage Survey for Infectious Disease Eligibility
RECRUITING
-
Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI